StockVS

SenesTech, Inc. (SNES) Analyse boursière

Matériaux de Base

SenesTech, Inc.

$1.82

+$0.01 (+0.55%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

SenesTech, Inc. is engaged in the specialized development and commercialization of technologies designed to manage animal pest populations via fertility control mechanisms. The company operates within the Basic Materials sector, specifically targeting the Specialty Chemicals industry, which implies a focus on high-value, niche chemical formulations rather than bulk commodity production. With a market capitalization of $8.49M and an annual revenue of $2.22M, the firm maintains a modest operational scale supported by a workforce of 23 employees. These valuation and revenue figures indicate that SenesTech functions as a micro-cap entity with a relatively small market footprint, suggesting limited revenue diversification and a reliance on its specific proprietary technologies for income generation. The low employee count relative to the market cap further underscores the capital-intensive nature of its chemical development processes or a highly automated production model typical in the specialty materials sector.

Santé financière

The company reported a trailing twelve-month revenue of $2.22M alongside a net income of $-6,383,000 and an EBITDA of $-6,370,000. The significant gap between the positive revenue figure and the substantial negative net income reveals a cost structure where operating expenses, including cost of goods sold and overhead, far exceed total sales proceeds. Furthermore, the free cash flow stands at $-3,711,375, indicating that the business is currently burning cash rather than generating liquidity, which severely limits its financial flexibility for organic expansion or capital expenditures without external financing. The gross margin is reported at 62.5%, suggesting that the core production costs are well-controlled relative to sales, yet this profitability is completely eroded by the operating margin of -446.8% and the profit margin of -287.4%. These deeply negative margins demonstrate that the company's overhead and administrative costs are disproportionately high compared to its revenue base. Regarding solvency, SenesTech holds $8.57M in cash against $2.68M in debt, resulting in a debt-to-equity ratio of 27.98. Despite the high leverage ratio implied by the debt-to-equity figure, the substantial cash reserve suggests the balance sheet is not currently in a distressed leveraged state, as liquid assets significantly outpace liabilities. The current ratio is 12.61, which indicates an extremely strong short-term liquidity position, meaning the company possesses more than twelve dollars in current assets for every dollar of current liabilities. However, the return on equity is -105.7% and the return on assets is -50.4%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.

Évaluation de la valorisation

The valuation metrics present a complex picture with a P/E ratio (TTM) listed as N/A due to losses and a forward P/E of -0.36. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in a period of negative earnings growth or anticipated losses rather than traditional earnings expansion. The price-to-book ratio is 0.87, indicating that the market is valuing the company at a discount to its book value, which often occurs when investors discount assets that may be difficult to liquidate or when future earnings potential is uncertain. Alternative valuation measures such as the price-to-sales ratio of 3.82 and an EV/EBITDA of -0.41 suggest that the stock is trading at a premium relative to its sales, which is unusual for a loss-making firm, while the negative EV/EBITDA confirms that earnings-based valuations are not currently applicable. The stock price has fluctuated significantly within a 52-week range, with a high of $6.24 and a low of $1.31. Without the specific current share price provided in the facts, the position relative to this range cannot be calculated, but the wide spread between the high and low suggests high volatility potential. The beta value is 0.25, which indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting it may be less sensitive to general market movements.

Growth & Income

SenesTech, Inc. is experiencing a contraction in its top line with a revenue growth rate of -16.0% year over year, while earnings growth is listed as N/A due to the absence of profitable earnings. Since the company is unprofitable, a direct comparison of earnings growth versus revenue growth is not feasible, but the negative revenue growth implies that the business is shrinking in terms of sales volume or pricing power. As a non-dividend payer, the company offers a dividend yield of N/A and a payout ratio of 0.0%, meaning no cash is distributed to shareholders from earnings. This 0.0% payout ratio is inherently sustainable given the lack of net income, as the company reinvests its limited resources or existing cash reserves into its development pipeline and operational continuity rather than distributing income. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, reflecting a stage of business focused on survival and product development rather than shareholder returns.

Comparaison avec les pairs

SenesTech, Inc. (SNES) opère dans le secteur Chimie de Spécialité. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
SenesTech, Inc. SNES $9.65M N/A
Linde plc LIN $238.09B 34.1
The Sherwin-Williams Company SHW $76.77B 29.9
Ecolab Inc. ECL $71.55B 34.4

Le ratio P/E moyen du secteur Chimie de Spécialité est de 54.8x. SenesTech, Inc. se négocie à un P/E de N/A.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de SenesTech, Inc.

SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption. It also develops Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice. The company was incorporated in 2004 and is headquartered in Surprise, Arizona.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation
$9.65M
Ratio P/E
N/A
Plus Haut 52 Sem.
$6.24
Plus Bas 52 Sem.
$1.41
Volume Moyen
76.51K

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
NASDAQ
Pays
United States
Employés
23